University of British Columbia
Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer
Abstract
dc:descriptionPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate below 10%, largely due to late-stage diagnosis and the absence of effective, non-invasive screening strategies. Although circulating tumor DNA (ctDNA) analysis from plasma has shown promise for molecular detection and monitoring, blood-based liquid biopsy remains operator-dependent and may lack sensitivity in early or low-burden disease. There is a critical need for alternative, patient-friendly biofluids that enable accessible and sensitive tumor detection. This thesis investigates the feasibility and analytical performance of urine-derived transrenal tumor DNA (trtDNA) as a non-invasive liquid biopsy for detecting oncogenic KRAS hotspot mutations (G12/G13), which occur in over 90% of PDAC cases. A pilot study of patients with PDAC and other gastrointestinal malignancies was enrolled through the BC Cancer Agency in Vancouver. Paired urine and plasma samples were collected using preservative-based kits, followed by optimized cell-free DNA extraction using a Q-Sepharose resin protocol designed to enrich short DNA fragments. KRAS mutations were quantified using droplet digital PCR (ddPCR), and results were integrated with clinical, pathological, and renal function data to assess detection sensitivity, concordance across biofluids, longitudinal dynamics, and patient feasibility. KRAS mutations were detected in urine-derived cfDNA in 10 of 10 primary KRAS-positive cases. Urinary trtDNA demonstrated consistently high mutant fractional abundance, frequently exceeding levels observed in matched plasma samples. Detected mutation profiles (including G12D, G12V, G12A, and G13D) were concordant with tumor tissue genotypes. However, a positive urine signal in one patient with a tissue-confirmed Q61R variant outside the assay panel remained unresolved. Q-Sepharose extraction yielded higher mutant FA than the commercial extraction comparator. No statistically significant associations were observed between urine FA and serum creatinine or eGFR in this small cohort. Urine collection and processing were feasible, and seven of ten participants rated urine collection as easy. Together, these findings demonstrate that urine-based trtDNA analysis is a feasible, sensitive, and patient-accepted approach for detecting KRAS mutations in PDAC. While limited by sample size and technical variability, this work provides proof-of-concept that urine-derived liquid biopsy can capture biologically meaningful tumor signals and may complement or outperform plasma-based ctDNA analysis.
Degree
thesis:*- Name thesis:degree_name
- Master of Science - MSc
- Level thesis:degree_level
- master's
- Discipline thesis:degree_discipline
- Interdisciplinary Oncology
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Singh, Sara
- Contributors dc:contributor
-
- Schrader, Kasmintan A.
- Karsan, Aly
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/95755